Skip to main content
. 2018 May;10(Suppl 13):S1438–S1446. doi: 10.21037/jtd.2018.05.130

Figure 3.

Figure 3

A 64-year-old male patient with NSCLC in treatment with pembrolizumab (anti-PD-L1 monoclonal antibody). Axial chest CT shows pneumonitis characterized by peri-bronchial confluent parenchymal consolidation in the right lung in association with bilateral ground-glass opacities. NSCLC, non-small cell lung cancer.